Esperion Therapeutics完成对Corstasis Therapeutics的收购,凭借Enbumyst™(布美他尼鼻喷雾剂)拓展心血管产品线

美股速递
Apr 03

Esperion Therapeutics Inc. (ESPR) 已正式完成对Corstasis Therapeutics的收购,此举显著增强了其在心血管疾病治疗领域的布局。通过此次交易,Esperion获得了Enbumyst™(布美他尼鼻喷雾剂)这一创新资产,进一步丰富了其心血管产品组合。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10